Postmenopausal bleeding and endometrial cancer
- Approach to a problem
Any bleeding after menopause must be checked. Usually it is thin, dry tissue, but in about one in ten women it is the first, early sign of endometrial cancer.
See it in 3D: Body of uterus · Fundus of uterus · Cervix
What it is
Postmenopausal bleeding is any bleeding from the genital tract more than 12 months after the last period. The commonest cause is atrophy of the endometrium or vagina; others are polyps, hyperplasia, hormone therapy, cervical lesions and endometrial cancer, found in roughly 5 to 10 percent. Endometrial cancer is the commonest gynaecological cancer in high-income countries and is rising with obesity; because it bleeds early, most cases are found at stage I and cured with surgery. The workup is a transvaginal ultrasound to measure the endometrial thickness, and endometrial sampling when it is thick or the bleeding persists.
Red flags
- Any bleeding after menopause, even a single episode of spotting.
- Risk factors: obesity, diabetes, polycystic ovary syndrome, never having been pregnant, late menopause, oestrogen without progestogen, tamoxifen, Lynch syndrome.
- Endometrial thickness above about 4 mm on transvaginal ultrasound in a woman not on hormones.
- Persistent or recurrent bleeding even with a thin endometrium.
Step-by-step approach
- Confirm the bleeding is from the genital tract (not urine or rectum) and ask about hormone therapy and tamoxifen.
- Examine the vulva, vagina and cervix; take cervical screening if due and biopsy any visible lesion.
- Transvaginal ultrasound: endometrial thickness and focal lesions.
- Thin (4 mm or less) and a single episode: likely atrophy; treat and observe.
- Thick, focal lesion, or recurrent bleeding: endometrial biopsy (office sampling) or hysteroscopy with biopsy.
- Cancer or atypical hyperplasia: refer to gynaecological oncology for staging and surgery.
Two kinds of endometrial cancer
| Feature | Type I (endometrioid) | Type II (serous, clear cell) |
|---|---|---|
| Share | Most cases | Fewer cases, more deaths |
| Driver | Excess oestrogen without progesterone | Not oestrogen-driven |
| Precursor | Atypical hyperplasia | Atrophic endometrium, intraepithelial carcinoma |
| Typical woman | Around menopause, obesity, diabetes | Older, thin |
| Molecular | PTEN, mismatch-repair loss (Lynch) | TP53 mutation |
| Prognosis | Usually good | Aggressive, spreads early |
Keys to the differential
- Tamoxifen thickens and distorts the endometrium on ultrasound, so women on it who bleed go straight to sampling or hysteroscopy.
- Atypical hyperplasia carries a high risk of coexisting or future cancer and is usually treated with hysterectomy.
- Molecular classification of endometrial cancer (for example mismatch-repair status) now guides treatment and screening for Lynch syndrome.
Next step / Initial management
- Refer urgently every woman with postmenopausal bleeding for ultrasound and, if needed, sampling within the time the national pathway sets.
- Benign findings: treat atrophy (vaginal oestrogen) or remove polyps; review if bleeding recurs.
- Cancer or atypical hyperplasia: refer to gynaecological oncology for staging and hysterectomy with removal of tubes and ovaries.
- Women with Lynch syndrome need specialist surveillance and discussion of risk-reducing surgery.
Common traps
- A little spotting after menopause is just hormones or atrophy: atrophy is the commonest cause, but only an ultrasound or biopsy can exclude endometrial cancer, so every episode is investigated.
- Being reassured by a thin endometrium when bleeding keeps recurring: sample anyway.
- Relying on ultrasound in a woman on tamoxifen: it thickens the lining even without cancer.
- Starting oestrogen-only therapy in a woman with a uterus: it causes hyperplasia and cancer unless a progestogen is added.
Test yourself
Think of the answer, then tap the question to see it.
A 62-year-old with obesity and diabetes has one episode of spotting. Ultrasound shows a 9 mm endometrium. What is next?
Endometrial sampling (office biopsy or hysteroscopy), because a thick endometrium after menopause needs histology to exclude cancer.
Why does obesity raise the risk of endometrial cancer?
Fat tissue converts androgens to oestrogen, giving long exposure to oestrogen without progesterone, which drives endometrial growth and hyperplasia.
Why must a woman with a uterus not receive oestrogen-only hormone therapy?
Unopposed oestrogen stimulates the endometrium and causes hyperplasia and cancer; a progestogen protects it.
Elsewhere in DurgiPedia
Connections
See it in 3D3
The structures of Durgical's 3D anatomy where it is found.
← All of obstetrics and gynaecology
Educational content; it does not replace assessment by a doctor or your institution's protocols, and it contains no doses. For heavy bleeding, a severe headache or blurred vision, a seizure, fever, strong abdominal pain or fewer baby movements, go to an emergency department at once.
Sources: Endometrial Cancer (StatPearls Publishing (NCBI Bookshelf), 2024); Endometrial Cancer Treatment (PDQ®), health professional version (National Cancer Institute (US), 2025); Lynch syndrome (MedlinePlus Genetics (U.S. National Library of Medicine), 2024).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
